National Cancer Institute; Notice of Closed Meetings, 15226 [2015-06477]
Download as PDF
<![CDATA[
15226
Federal Register / Vol. 80, No. 55 / Monday, March 23, 2015 / Notices
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; New
Approaches to Synthetic Lethality for Mutant
KRas-Dependent Cancers (U01).
Date: April 13, 2015.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove; 9609 Medical Center Drive; Room
7W032; Rockville, MD 20850; (Telephone
Conference Call).
Contact Person: Clifford W. Schweinfest,
Ph.D.; Scientific Review Officer; Special
Review Branch; Division of Extramural
Activities; National Cancer Institute, NIH;
9609 Medical Center Drive, Room 7W108;
Bethesda, MD 20892–9750; 240–276–6343;
schweinfestcw@mail.nih.gov.
Name of Committee: National Cancer
Institute Initial Review Group; Subcommittee
A—Cancer Centers.
Date: May 7, 2015.
Time: 8:00 a.m. to 4:45 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda;
(Formerly Holiday Inn Select); 8120
Wisconsin Avenue; Bethesda, MD 20814.
Contact Person: Shamala K. Srinivas,
Ph.D.; Associate Director; Office of Referral,
Review, and Program Coordination; Division
of Extramural Activities; National Cancer
Institute, NIH; 9609 Medical Center Drive,
7W530; Bethesda, MD 20892–9750; 240–276–
6442; ss537t@nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/sep/sep.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
VerDate Sep<11>2014
16:51 Mar 20, 2015
Jkt 235001
Dated: March 17, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–06477 Filed 3–20–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-up
Exclusive Evaluation Option License
Agreement: Pre-Clinical Evaluation
and Commercial Development of AntiTyrosine Kinase-Like Orphan Receptor
1 Antibody-Drug Conjugates for the
Treatment of Human Cancers
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of a
start-up exclusive evaluation option
license agreement to practice the
inventions embodied in U.S. Patent
Application No. 61/172,099 entitled
‘‘Anti-human ROR1 Antibodies’’ filed
April 23, 2009 [HHS Ref. E–097–2009/
0–US–01], PCT Application No. PCT/
US2010/032208 entitled ‘‘Anti-human
ROR1 Antibodies’’ filed April 23, 2010
[HHS Ref. E–097–2009/0–PCT–02],
European Patent Application No.
10715077.3 entitled, ‘‘Anti-human
ROR1 Antibodies’’ filed October 24,
2011 [HHS Ref. No. E–097–2009/0–EP–
03], U.S. Patent Application No. 13/
265,582 entitled, ‘‘Anti-human ROR1
Antibodies’’ filed October 21, 2011
[HHS Ref. No. E–097–2009/0–US–04],
Australian Patent Application No.
2010238723 entitled, ‘‘Anti-human
ROR1 Antibodies’’ filed October 21,
2011 [HHS Ref. No. E–097–2009/0–AU–
04], Canadian Patent Application No.
2,759,733 entitled, ‘‘Anti-human ROR1
Antibodies’’ filed October 21, 2011
[HHS Ref. No. E–097–2009/0–CA–05],
US Provisional Application No. 61/
418,550 entitled, ‘‘Chimeric rabbit/
human ROR1 antibodies’’ filed
December 1, 2010 [HHS Ref. E–039–
2011/0–US–01], PCT Application No.
PCT/US2011/062670 entitled,
‘‘Chimeric rabbit/human ROR1
antibodies’’ filed November 30, 2011
[HHS Ref. E–039–2011/0–PCT–02];
SUMMARY:
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Australian Patent Application No.
2011336650 entitled, ‘‘Chimeric rabbit/
human ROR1 antibodies’’ filed
November 30, 2011 [HHS Ref. E–039–
2011/0–AU–03], Canadian Patent
Application No. 2818992 entitled,
‘‘Chimeric rabbit/human ROR1
antibodies’’ filed November 30, 2011
[HHS Ref. E–039–2011/0–CA–04],
European Patent Application No.
11791733.6 entitled, ‘‘Chimeric rabbit/
human ROR1 antibodies’’ filed
November 30, 2011 [HHS Ref. E–039–
2011/0–EP–05] and U.S. Patent
Application No. 13/990,977 entitled,
‘‘Chimeric rabbit/human ROR1
antibodies’’ filed May 31, 2013 [HHS
Ref. E–039–2011/0–US–06] and all
related continuing and foreign patents/
patent applications for the technology
family to NBE Therapeutics, Ltd. The
patent rights in these inventions have
been assigned to the Government of the
United States of America.
The prospective start-up exclusive
evaluation option license territory may
be worldwide and the field of use may
be limited to pre-clinical evaluation and
commercial development of an
antibody-drug conjugate comprising an
anti-tyrosine protein kinase
transmembrane receptor (ROR1)
antibody for the treatment of human
ROR1 expressing cancers utilizing
enzymatic conjugation methods linking
a small molecule to a full-length
antibody, wherein the full-length
antibody moiety comprises the antiROR1 antibodies or CDR3s within the
scope of the Licensed Patent Rights. For
avoidance of doubt, this Agreement
explicitly excludes the following: (a)
Antibody-drug conjugates utilizing nonenzymatic conjugation linking small
molecules to said antibodies, (b)
immunotoxins comprising anti-ROR1
antibodies and Pseudomonas exotoxins,
and (c) non-full-length bispecific
antibodies. Upon expiration or
termination of the start-up exclusive
evaluation option license, NBE
Therapeutics, Ltd. will have the right to
execute a start-up exclusive patent
commercialization license which will
supersede and replace the start-up
exclusive evaluation option license with
no broader territory than granted in the
start-up exclusive evaluation option
license and the field of use will be
commensurate with the commercial
development plan at the time of
conversion.
Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before April
6, 2015 will be considered.
DATED:
E:\FR\FM\23MRN1.SGM
23MRN1
]]>Agencies
[Federal Register Volume 80, Number 55 (Monday, March 23, 2015)]
[Notices]
[Page 15226]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-06477]
[[Page 15226]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; New Approaches to Synthetic Lethality for Mutant KRas-
Dependent Cancers (U01).
Date: April 13, 2015.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove; 9609 Medical
Center Drive; Room 7W032; Rockville, MD 20850; (Telephone Conference
Call).
Contact Person: Clifford W. Schweinfest, Ph.D.; Scientific
Review Officer; Special Review Branch; Division of Extramural
Activities; National Cancer Institute, NIH; 9609 Medical Center
Drive, Room 7W108; Bethesda, MD 20892-9750; 240-276-6343;
schweinfestcw@mail.nih.gov.
Name of Committee: National Cancer Institute Initial Review
Group; Subcommittee A--Cancer Centers.
Date: May 7, 2015.
Time: 8:00 a.m. to 4:45 p.m.
Agenda: To review and evaluate grant applications.
Place: Doubletree Hotel Bethesda; (Formerly Holiday Inn Select);
8120 Wisconsin Avenue; Bethesda, MD 20814.
Contact Person: Shamala K. Srinivas, Ph.D.; Associate Director;
Office of Referral, Review, and Program Coordination; Division of
Extramural Activities; National Cancer Institute, NIH; 9609 Medical
Center Drive, 7W530; Bethesda, MD 20892-9750; 240-276-6442;
ss537t@nih.gov.
Information is also available on the Institute's/Center's home
page: https://deainfo.nci.nih.gov/advisory/sep/sep.htm, where an
agenda and any additional information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: March 17, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-06477 Filed 3-20-15; 8:45 am]
BILLING CODE 4140-01-P
